MedTrace Logo

Effectiveness Study of the Guardian RT in Type 1 Diabetics

NCT01331343 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2011-04-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether Type 1 diabetic patients using the Guardian RT glucose sensor can improve glycemic control over a 12-week period, compared to patients using self-monitoring blood glucose testing (SMBG) alone.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DEVICE

Guardian RT Telemetered Glucose Monitoring System

Sponsors & Collaborators

  • Medtronic Diabetes

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • France
  • Germany
  • Israel
  • Italy
  • Slovenia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01331343 on ClinicalTrials.gov